{"id":11510,"date":"2026-05-29T12:56:49","date_gmt":"2026-05-29T10:56:49","guid":{"rendered":"https:\/\/shams-alyaoum.com\/en\/?p=11510"},"modified":"2026-05-29T12:56:49","modified_gmt":"2026-05-29T10:56:49","slug":"aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine","status":"publish","type":"post","link":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","title":{"rendered":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine"},"content":{"rendered":"<p><b>SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects<\/b><\/p>\n<div class=\"content  content-justify \">\n<p>The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo.<\/p>\n<p>Curevo\u2019s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI\u2019s proprietary SLA-SE adjuvant. The acquisition underscores the growing recognition of next-generation adjuvants that can deliver improved tolerability and strong immune responses.<\/p>\n<p>\u201cSLA-SE represents a significant advancement in adjuvant technology, designed to elicit robust T-cell immunity with a favorable safety profile,\u201d said Keeley Foley, CEO of AAHI. \u201cWe are thrilled that this technology, developed at AAHI, is now positioned to reach people through Lilly\u2019s world-class development and commercial capabilities.\u201d<\/p>\n<p>Importantly, AAHI retains rights to license and develop SLA-SE adjuvant for uses outside the shingles (varicella zoster virus) vaccine field. This includes in combination with other antigens for a wide range of infectious diseases, cancer vaccines, and additional indications.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead asset, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":11511,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[9,1310,1392],"class_list":["post-11510","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-business","tag-general","tag-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum\" \/>\n<meta property=\"og:description\" content=\"SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead asset, &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Magazine Shams Al Yaoum\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T10:56:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"666\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"shamsalyaoum\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"shamsalyaoum\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\",\"url\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\",\"name\":\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum\",\"isPartOf\":{\"@id\":\"https:\/\/shams-alyaoum.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg\",\"datePublished\":\"2026-05-29T10:56:49+00:00\",\"author\":{\"@id\":\"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199\"},\"breadcrumb\":{\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage\",\"url\":\"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg\",\"contentUrl\":\"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg\",\"width\":1000,\"height\":666},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/shams-alyaoum.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/#website\",\"url\":\"https:\/\/shams-alyaoum.com\/en\/\",\"name\":\"Magazine Shams Al Yaoum\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/shams-alyaoum.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199\",\"name\":\"shamsalyaoum\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g\",\"caption\":\"shamsalyaoum\"},\"url\":\"https:\/\/shams-alyaoum.com\/en\/author\/shamsalyaoum\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum","og_description":"SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead asset, &hellip;","og_url":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","og_site_name":"Magazine Shams Al Yaoum","article_published_time":"2026-05-29T10:56:49+00:00","og_image":[{"width":1000,"height":666,"url":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg","type":"image\/jpeg"}],"author":"shamsalyaoum","twitter_card":"summary_large_image","twitter_misc":{"Written by":"shamsalyaoum","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","url":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","name":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Magazine Shams Al Yaoum","isPartOf":{"@id":"https:\/\/shams-alyaoum.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg","datePublished":"2026-05-29T10:56:49+00:00","author":{"@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199"},"breadcrumb":{"@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage","url":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg","contentUrl":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2026\/05\/1-20.jpg","width":1000,"height":666},{"@type":"BreadcrumbList","@id":"https:\/\/shams-alyaoum.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/shams-alyaoum.com\/en\/"},{"@type":"ListItem","position":2,"name":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/shams-alyaoum.com\/en\/#website","url":"https:\/\/shams-alyaoum.com\/en\/","name":"Magazine Shams Al Yaoum","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/shams-alyaoum.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199","name":"shamsalyaoum","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g","caption":"shamsalyaoum"},"url":"https:\/\/shams-alyaoum.com\/en\/author\/shamsalyaoum\/"}]}},"_links":{"self":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/11510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/comments?post=11510"}],"version-history":[{"count":1,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/11510\/revisions"}],"predecessor-version":[{"id":11512,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/11510\/revisions\/11512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/media\/11511"}],"wp:attachment":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/media?parent=11510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/categories?post=11510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/tags?post=11510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}